EG24660A - Pharaceutical composition of olanzapine and fluoxetine for treatment of psychoses - Google Patents

Pharaceutical composition of olanzapine and fluoxetine for treatment of psychoses

Info

Publication number: EG24660A
Authority: EG; Egypt
Prior art keywords: psychoses; olanzapine; fluoxetine; treatment; pharaceutical
Prior art date: 1996-09-23

Application number

EG98197A

Other languages

English (en)

Inventor

Franklin P Bymaster

Kenneth W Perry

Gary D Tollefson

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-09-23

Filing date

1997-09-23

Publication date

2010-04-07

1997-09-23 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2010-04-07 Application granted granted Critical

2010-04-07 Publication of EG24660A publication Critical patent/EG24660A/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

EG98197A 1996-09-23 1997-09-23 Pharaceutical composition of olanzapine and fluoxetine for treatment of psychoses EG24660A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US2688496P	1996-09-23	1996-09-23

Publications (1)

Publication Number	Publication Date
EG24660A true EG24660A (en)	2010-04-07

Family

ID=21834363

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EG98197A EG24660A (en)	1996-09-23	1997-09-23	Pharaceutical composition of olanzapine and fluoxetine for treatment of psychoses

Country Status (30)

Country	Link
US (1)	US6147072A (zh)
EP (1)	EP0830864B9 (zh)
JP (1)	JP2001503031A (zh)
KR (1)	KR100532901B1 (zh)
CN (1)	CN1162156C (zh)
AR (1)	AR008462A1 (zh)
AT (1)	ATE231724T1 (zh)
AU (1)	AU719033C (zh)
BR (1)	BR9711530A (zh)
CA (1)	CA2264941C (zh)
CO (1)	CO4900058A1 (zh)
CZ (1)	CZ301154B6 (zh)
DE (1)	DE69718731T2 (zh)
DK (1)	DK0830864T3 (zh)
EA (1)	EA001317B1 (zh)
EG (1)	EG24660A (zh)
ES (1)	ES2191152T3 (zh)
HK (1)	HK1009755A1 (zh)
HU (1)	HU228178B1 (zh)
IL (2)	IL128730A0 (zh)
MY (1)	MY125564A (zh)
NO (1)	NO319166B1 (zh)
NZ (1)	NZ334168A (zh)
PE (1)	PE110198A1 (zh)
PL (1)	PL190374B1 (zh)
RS (1)	RS49828B (zh)
TW (1)	TW541178B (zh)
UA (1)	UA62937C2 (zh)
WO (1)	WO1998011897A1 (zh)
ZA (1)	ZA977967B (zh)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0901786B1 (en)	1997-08-11	2007-06-13	Pfizer Products Inc.	Solid pharmaceutical dispersions with enhanced bioavailability
KR100398791B1 (ko) *	1998-04-24	2003-09-19	스카리스타 리미티드	우울증 치료 및 그 용도의 약리학적 제제
CA2332814C (en) *	1998-05-22	2008-11-04	Eli Lilly And Company	Combination therapy for treatment of refractory depression
US6960577B2 (en)	1998-05-22	2005-11-01	Eli Lilly And Company	Combination therapy for treatment of refractory depression
CA2332408A1 (en) *	1998-05-29	1999-12-09	Eli Lilly And Company	Combination therapy for treatment of bipolar disorders
AU1321900A (en) *	1998-10-23	2000-05-15	Sepracor, Inc.	Compositions and methods employing r(-) fluoxetine and other active ingredients
US6174882B1 (en) *	1998-11-23	2001-01-16	Sepracor Inc.	2-hydroxymethylolanzapine compositions and methods
ES2306646T3 (es) *	1999-02-09	2008-11-16	Pfizer Products Inc.	Composiciones de farmacos basicos con biodisponibilidad incrementada.
US6706283B1 (en) *	1999-02-10	2004-03-16	Pfizer Inc	Controlled release by extrusion of solid amorphous dispersions of drugs
WO2000054775A1 (de)	1999-03-12	2000-09-21	Basf Ag	Stabile pharmazeutische anwendungsform für paroxetin-anhydrat
AU4552200A (en) *	1999-05-12	2000-12-05	Solvay Pharmaceuticals B.V.	Method of treating psychotic disorders
AU4598400A (en) *	1999-05-19	2000-12-12	Astrazeneca Ab	Method of treatment
EP1189662A1 (en) *	1999-06-09	2002-03-27	Eli Lilly And Company	Combination for treating weight gain associated with antipsychotic use comprising an atypical antipsychotic and an h2 antagonist
AR021155A1 (es) *	1999-07-08	2002-06-12	Lundbeck & Co As H	Tratamiento de desordenes neuroticos
AU7405000A (en) *	1999-09-28	2001-04-30	H. Lundbeck A/S	Melt granulated composition and modified release dosage form prepared from said composition
US6476051B2 (en)	1999-12-17	2002-11-05	Bristol-Myers Squibb Company	Antipsychotic heterocycle compounds
GEP20053427B (en) *	1999-12-23	2005-01-25	Pfizer Prod Inc	Pharmaceutical Compositions Providing Enhanced Drug Concentrations
US6572890B2 (en) *	2000-01-13	2003-06-03	Osmotica Corp.	Osmotic device containing venlafaxine and an anti-psychotic agent
AU2001268055A1 (en) *	2000-06-30	2002-01-14	Eli Lilly And Company	Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist
US7666445B2 (en) *	2000-10-20	2010-02-23	The Trustees Of The University Of Pennsylvania	Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use
US20030232881A1 (en) *	2000-10-27	2003-12-18	H. Lundbeck A/S	Crystals of pharmaceutically acceptable salts of citalopram, methods of crystallization, and pharmaceutical compositions comprising them
CA2364211A1 (en) *	2000-12-05	2002-06-05	Phillip Branch Chappell	Combination treatment for depression, anxiety and psychosis
JP2004517112A (ja)	2001-01-02	2004-06-10	ファルマシア・アンド・アップジョン・カンパニー	新規薬物コンビネーション
JP2004518699A (ja) *	2001-02-06	2004-06-24	アストラゼネカ・アクチエボラーグ	クエチアピンを用いた物質乱用の治療方法
US20020123490A1 (en) *	2001-03-01	2002-09-05	Pfizer Inc.	Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis
MEP5908A (xx) *	2001-05-01	2010-02-10	Lundbeck & Co As H	Upotreba enantiomerno čistog escitaloprama
US7034059B2 (en)	2001-07-02	2006-04-25	Sepracor Inc.	Methods of using norfluoxetine
EP1551393A4 (en) *	2002-07-30	2010-06-16	Peter Migaly	COMBINATION OF THERAPY FOR DEPRESSION, PREVENTION OF SUICIDE AND VARIOUS MEDICAL AND PSYCHIATRIC DISORDERS
US20070077301A1 (en) *	2002-12-23	2007-04-05	Meyer Glenn A	Venlafaxine osmotic device formulation
AU2003295235B2 (en)	2002-12-27	2008-06-19	Otsuka Pharmaceutical Co., Ltd.	Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
AR042806A1 (es)	2002-12-27	2005-07-06	Otsuka Pharma Co Ltd	Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
MXPA05012392A (es) *	2003-05-16	2006-02-02	Pfizer Prod Inc	Tratamientos de ansiedad con ziprasidona.
WO2004100954A1 (en) *	2003-05-16	2004-11-25	Pfizer Products Inc.	Treatment of psychotic and depressive disorders
BRPI0419067A (pt) *	2003-05-16	2007-12-11	Pfizer Prod Inc	método para aumento da cognição utilizando ziprasidona
NZ527142A (en) *	2003-07-23	2006-03-31	Douglas Pharmaceuticals Ltd	A stable suspension formulation
US20050032781A1 (en) *	2003-08-06	2005-02-10	Elliot Ehrich	Methods for administering active agents to CYP 2D6 sensitive patients
EP1547650A1 (en) *	2003-12-02	2005-06-29	B & B Beheer NV	Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
PL1708790T3 (pl)	2003-12-02	2010-10-29	Pharmaneuroboost N V	Zastosowanie pipamperonu oraz antagonisty receptora D2 lub antagonisty receptora serotoniny/dopaminy do leczenia zaburzeń psychotycznych
WO2005053703A1 (en)	2003-12-02	2005-06-16	Leslie James Sheldon	Combination therapy for dementia, depression and apathy
US7855195B2 (en)	2003-12-02	2010-12-21	Pharmaneuroboost N.V.	Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7884096B2 (en)	2003-12-02	2011-02-08	Pharmaneuroboost N.V.	Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
CN1964713A (zh) *	2003-12-23	2007-05-16	达法尔摩公司	多巴胺－受体结合化合物的共同使用
EP2633853A1 (en) *	2004-01-12	2013-09-04	The Trustees of The University of Pennsylvania	Long-term delivery formulations and methods of use thereof
US8221778B2 (en)	2005-01-12	2012-07-17	The Trustees Of The University Of Pennsylvania	Drug-containing implants and methods of use thereof
US20050171088A1 (en) *	2004-01-30	2005-08-04	Astrazeneca Ab	Treatment of psychoses with dibenzothiazepine antipsychotic
WO2006027800A1 (en) *	2004-09-06	2006-03-16	Shasun Chemicals And Drugs Limited	A novel process for preparation of a pharmaceutically pure polymorphic form 1 of olanzapine
WO2006083204A1 (en) *	2004-12-27	2006-08-10	Alpha 2 Pharmaceutical Ab	Antidepressant medicament comprising idazoxan and a selective serotonin reuptake inhibitor
CZ200563A3 (cs) *	2005-02-02	2006-10-11	Zentiva, A. S.	Lécivý prípravek obsahující jako úcinnou slozku olanzapin a zpusob jeho výroby
UA97349C2 (uk) *	2005-09-08	2012-02-10	Х. Луннбэк А/С	Стійкі тверді склади сертиндолу
US20070093471A1 (en) *	2005-10-26	2007-04-26	Alamo Pharmaceuticals, Llc	Compositions and methods for the administration clozapine formulations which modulate body weight
NZ599031A (en) *	2007-02-09	2013-11-29	Alphapharm Pty Ltd	A dosage form containing two or more active pharmaceutical ingredients in different physical forms
WO2008122019A1 (en) *	2007-04-02	2008-10-09	Cypress Biosciences, Inc.	Improving the tolerability of both mirtazapine and reboxetine by using them in combination
WO2008128166A1 (en) *	2007-04-13	2008-10-23	Concert Pharmaceuticals Inc.	Deuterated derivatives of 4-(6-fluoro-1, 2-benzisoxazol-3-yl) piperidine compounds
RU2508096C2 (ru) *	2007-08-01	2014-02-27	Сергей Олегович Бачурин	Способы и композиции для лечения шизофрении с использованием нейролептической комбинированной терапии
RU2508106C2 (ru) *	2007-08-01	2014-02-27	Сергей Олегович Бачурин	Способы и композиции для лечения шизофрении с использованием атипичной нейролептической комбинированной терапии
MY157192A (en) *	2007-08-03	2016-05-13	Richter Gedeon Nyrt	Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands
CA2712282A1 (en) *	2008-01-25	2009-07-30	Alphapharm Pty Ltd	Delayed release pharmaceutical composition of duloxetine
WO2011018801A2 (en) *	2009-08-12	2011-02-17	Genepharm India Pvt Ltd	Solid oral dosage form of ziprasidone
WO2011057176A1 (en) *	2009-11-06	2011-05-12	Forest Laboratories Holding Limited	Novel crystalline forms of (1s,2r)-2-(amino methyl)-n,n-diethyl-1-phenyl cyclopropane carboxamide
JP6440625B2 (ja)	2012-11-14	2018-12-19	ザ・ジョンズ・ホプキンス・ユニバーシティー	精神分裂病を処置するための方法および組成物
AU2014361813A1 (en) *	2013-12-13	2016-07-28	Ralph ANKENMAN	Compositions and methods for treating dysregulated systems
NZ760790A (en) *	2014-02-07	2022-11-25	Neurocrine Biosciences Inc	Pharmaceutical compositions comprising an antipsychotic drug and a vmat2 inhibitor and uses thereof
CN115304596A (zh)	2015-10-30	2022-11-08	纽罗克里生物科学有限公司	Valbenazine盐及其多晶形物
LT3394057T (lt)	2015-12-23	2022-06-27	Neurocrine Biosciences, Inc.	Sintezės būdas, skirtas pagaminti (s)-(2r,3r,11br)-3-izobutil-9,10-dimetoksi-2,3,4,6,7,11b-heksahidro-1h-pirido[2,1-a]izochinolin-2-ilo 2-amino-3-metilbutanoato di(4-metilbenzensulfonatą)
US10336679B2 (en) *	2016-10-24	2019-07-02	Syneurx International (Taiwan) Corp.	Polymorphic forms of sodium benzoate and uses thereof
CN110740732A (zh)	2017-01-27	2020-01-31	纽罗克里生物科学有限公司	施用某些vmat2抑制剂的方法
US20200276184A1 (en)	2017-09-21	2020-09-03	Neurocrine Biosciences, Inc.	High Dosage Valbenazine Formulation and Compositions, Methods, and Kits Related Thereto
US10993941B2 (en)	2017-10-10	2021-05-04	Neurocrine Biosciences, Inc.	Methods for the administration of certain VMAT2 inhibitors
US20200230127A1 (en)	2017-10-10	2020-07-23	Neurocrine Biosciences, Inc.	Methods for the Administration of Certain VMAT2 Inhibitors
WO2020037022A1 (en)	2018-08-15	2020-02-20	Neurocrine Biosciences, Inc.	Methods for the administration of certain vmat2 inhibitors
CN108938645A (zh) *	2018-08-24	2018-12-07	山西医科大学第医院	一种抗精神病药物组合物
CN108938635A (zh) *	2018-08-24	2018-12-07	山西医科大学第医院	一种低剂量非典型抗精神病药物组合物
CN108926569A (zh) *	2018-08-24	2018-12-04	山西医科大学第医院	一种非典型抗精神病药物组合物
US10940141B1 (en)	2019-08-23	2021-03-09	Neurocrine Biosciences, Inc.	Methods for the administration of certain VMAT2 inhibitors
CN111084778B (zh) *	2019-12-31	2022-06-24	北京鑫开元医药科技有限公司	一种奥氮平盐酸氟西汀胶囊及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4314081A (en) *	1974-01-10	1982-02-02	Eli Lilly And Company	Arloxyphenylpropylamines
US5114976A (en) *	1989-01-06	1992-05-19	Norden Michael J	Method for treating certain psychiatric disorders and certain psychiatric symptoms
US5229382A (en) *	1990-04-25	1993-07-20	Lilly Industries Limited	2-methyl-thieno-benzodiazepine
US5605897A (en) *	1991-04-23	1997-02-25	Eli Lilly And Company	2-methyl-thieno-benzodiazepine
WO1997035586A1 (en) *	1996-03-25	1997-10-02	Eli Lilly And Company	Method for treating pain
EP0906104A4 (en) *	1996-03-25	2003-12-10	Lilly Co Eli	PAIN TREATMENT PROCESS
US5846928A (en) *	1996-08-01	1998-12-08	Pasken Products Co., Ltd.	Method for treating cancer patients
US5877198A (en) *	1996-10-17	1999-03-02	Milkhaus Laboratory, Inc.	Treatment of urinary incontinence

1997
- 1997-09-04 ZA ZA977967A patent/ZA977967B/xx unknown
- 1997-09-09 CZ CZ0098799A patent/CZ301154B6/cs not_active IP Right Cessation
- 1997-09-09 EA EA199900324A patent/EA001317B1/ru not_active IP Right Cessation
- 1997-09-09 BR BR9711530A patent/BR9711530A/pt active Search and Examination
- 1997-09-09 NZ NZ334168A patent/NZ334168A/xx not_active IP Right Cessation
- 1997-09-09 CA CA002264941A patent/CA2264941C/en not_active Expired - Lifetime
- 1997-09-09 IL IL12873097A patent/IL128730A0/xx not_active IP Right Cessation
- 1997-09-09 CN CNB971981132A patent/CN1162156C/zh not_active Expired - Lifetime
- 1997-09-09 AU AU44112/97A patent/AU719033C/en not_active Expired
- 1997-09-09 PL PL97332481A patent/PL190374B1/pl unknown
- 1997-09-09 KR KR10-1999-7002422A patent/KR100532901B1/ko not_active IP Right Cessation
- 1997-09-09 JP JP10514717A patent/JP2001503031A/ja active Pending
- 1997-09-09 HU HU9903905A patent/HU228178B1/hu unknown
- 1997-09-09 UA UA99031565A patent/UA62937C2/uk unknown
- 1997-09-09 IL IL16183397A patent/IL161833A0/xx not_active IP Right Cessation
- 1997-09-09 WO PCT/US1997/015874 patent/WO1998011897A1/en not_active Application Discontinuation
- 1997-09-09 RS YUP-152/99A patent/RS49828B/sr unknown
- 1997-09-12 TW TW086113280A patent/TW541178B/zh not_active IP Right Cessation
- 1997-09-16 MY MYPI97004299A patent/MY125564A/en unknown
- 1997-09-19 CO CO97054849A patent/CO4900058A1/es unknown
- 1997-09-19 PE PE1997000840A patent/PE110198A1/es not_active Application Discontinuation
- 1997-09-19 AR ARP970104324A patent/AR008462A1/es active IP Right Grant
- 1997-09-22 ES ES97307375T patent/ES2191152T3/es not_active Expired - Lifetime
- 1997-09-22 DE DE69718731T patent/DE69718731T2/de not_active Expired - Lifetime
- 1997-09-22 EP EP97307375A patent/EP0830864B9/en not_active Expired - Lifetime
- 1997-09-22 DK DK97307375T patent/DK0830864T3/da active
- 1997-09-22 AT AT97307375T patent/ATE231724T1/de active
- 1997-09-23 EG EG98197A patent/EG24660A/xx active
- 1997-09-23 US US08/935,872 patent/US6147072A/en not_active Expired - Lifetime
1998
- 1998-09-21 HK HK98110801A patent/HK1009755A1/xx not_active IP Right Cessation
1999
- 1999-03-22 NO NO19991381A patent/NO319166B1/no not_active IP Right Cessation

Also Published As

Publication number	Publication date
HUP9903905A3 (en)	2001-03-28
HUP9903905A2 (hu)	2000-10-28
MY125564A (en)	2006-08-30
PL190374B1 (pl)	2005-12-30
CZ301154B6 (cs)	2009-11-18
BR9711530A (pt)	1999-08-24
ZA977967B (en)	1999-03-04
UA62937C2 (uk)	2004-01-15
IL128730A0 (en)	2000-01-31
CA2264941C (en)	2008-11-18
ES2191152T3 (es)	2003-09-01
CA2264941A1 (en)	1998-03-26
DK0830864T3 (da)	2003-05-26
KR20000048518A (ko)	2000-07-25
PL332481A1 (en)	1999-09-13
WO1998011897A1 (en)	1998-03-26
DE69718731T2 (de)	2003-09-11
JP2001503031A (ja)	2001-03-06
NO319166B1 (no)	2005-06-27
CZ98799A3 (cs)	1999-12-15
ATE231724T1 (de)	2003-02-15
RS49828B (sr)	2008-08-07
CN1162156C (zh)	2004-08-18
HU228178B1 (en)	2013-01-28
NO991381L (no)	1999-03-22
EA199900324A1 (ru)	1999-08-26
NO991381D0 (no)	1999-03-22
EP0830864A1 (en)	1998-03-25
YU15299A (sh)	2002-06-19
KR100532901B1 (ko)	2005-12-02
EA001317B1 (ru)	2001-02-26
CN1230886A (zh)	1999-10-06
AU719033C (en)	2005-08-04
AR008462A1 (es)	2000-01-19
NZ334168A (en)	2000-09-29
EP0830864B9 (en)	2003-09-03
TW541178B (en)	2003-07-11
AU4411297A (en)	1998-04-14
CO4900058A1 (es)	2000-03-27
HK1009755A1 (en)	1999-06-11
IL161833A0 (en)	2005-11-20
DE69718731D1 (de)	2003-03-06
EP0830864B1 (en)	2003-01-29
AU719033B2 (en)	2000-05-04
US6147072A (en)	2000-11-14
PE110198A1 (es)	1999-01-21

Publication	Publication Date	Title
EG24660A (en)	2010-04-07	Pharaceutical composition of olanzapine and fluoxetine for treatment of psychoses
PL333364A1 (en)	1999-12-06	Novel compounds and method of using them
GB9422571D0 (en)	1995-01-04	Haemorrihoidal compositions and method of use
AP2000001783A0 (en)	2000-06-30	Disinfectant and method of making
EP0964032A4 (en)	2000-07-12	NEW COMPOSITION AND TREATMENT
GB9617780D0 (en)	1996-10-02	Method of treatment
ZA989399B (en)	1999-04-15	Method and composition
HUP9901883A3 (en)	2000-09-28	Disinfecting composition and process for disinfecting surfaces
EP0835092A4 (en)	2000-05-10	COMPOSITION AND TREATMENT FOR THE CONTROL OF Baldness
GB9615682D0 (en)	1996-09-04	The process of asphalt purification and the composition of modified asphalt
GB2318356B (en)	1999-03-10	Composition and method
GB9814869D0 (en)	1998-09-09	Process and composition
EP1009433A4 (en)	2005-03-16	THERAPEUTIC COMPOSITION AND TREATMENT METHOD
ZA973988B (en)	1998-11-09	Method of treatment
GB9618341D0 (en)	1996-10-16	Method of treatment
GB9526675D0 (en)	1996-02-28	Bituminous composition and process
GB9617346D0 (en)	1996-10-02	Therapeutic methods and compositions for use therein
HU9601436D0 (en)	1996-07-29	Combination of moxa-suppositorium and homeopathic composition of ige allergene for treating mentioned allergias
GB9608927D0 (en)	1996-07-03	Method of treatment and pharmaceutical composition
PL332941A1 (en)	1999-10-25	Method of obtaining naphtyridinic compounds and novel intermediate compounds
HUP9600327A3 (en)	2000-12-28	Pharmaceutical composition for treating or profilacting meteoropathy and different kinetoses
GB9601656D0 (en)	1996-03-27	Novel composition and method
GB9619940D0 (en)	1996-11-13	Composition and method
ZA967176B (en)	1997-06-25	Composition and method
GB9603856D0 (en)	1996-04-24	Composition and method